Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | KMO | O15229 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23907984 | 0.86 | KMT2A (0.41) | KMT2APOLBMEN1GAASMN1; SMN2 | |
| SCHEMBL24253861 | 0.82 | KMT2A (0.40) | KMT2APOLBMEN1GAASMN1; SMN2 | |
| SCHEMBL30424219 | 0.82 | KMT2A (0.40) | KMT2APOLBMEN1GAASMN1; SMN2 | |
| SCHEMBL23884178 | 0.79 | KMT2A (0.37) | KMT2APOLBMEN1GAASMN1; SMN2 | |
| SCHEMBL30165262 | 0.79 | KMT2A (0.37) | KMT2APOLBMEN1GAASMN1; SMN2 | |
| SCHEMBL24350030 | 0.79 | JAK3 (0.35) | JAK3GRM5KMOCNR2 | |
| SCHEMBL31409663 | 0.76 | SCN9A (0.37) | KMT2APOLBMEN1GAASMN1; SMN2 | |
| SCHEMBL31409703 | 0.75 | SCN9A (0.36) | KMT2APOLBMEN1GAASMN1; SMN2 | |
| SCHEMBL991954 | 0.73 | POLB (0.44) | KMT2APOLBMEN1GAASMN1; SMN2 | |
| SCHEMBL25087989 | 0.73 | KMO (0.35) | JAK3GRM5KMOCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932626-B2 | 2-pyrimidone analogs as potent antiviral agents against Alphaviruses | SOUTHERN RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | disclosed |
| CN-115916175-A | Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses | 南方研究院 | 2023-04-04 | — | — | CN | disclosed |
| US-11566019-B2 | 2-pyrimidone analogs as potent antiviral agents against alphaviruses | SOUTHERN RESEARCH INSTITUTE (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-09 | — | — | US | disclosed |
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | SOUTHERN RES INST (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | KMT2A 2117/4885POLB 2683/4885JAK3 96/4885 |
| US-11566019-B2 | 2-pyrimidone analogs as potent antiviral agents against alphaviruses | EIF2AK2, ZC3HAV1, MAVS | KMT2A 2117/4885POLB 2683/4885JAK3 96/4885 |
| US-11932626-B2 | 2-pyrimidone analogs as potent antiviral agents against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | KMT2A 2117/4885POLB 2683/4885JAK3 96/4885 |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | KMT2A 2117/4885POLB 2683/4885JAK3 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.